For nearly two decades, Tim Friede, a 58-year-old resident of Wisconsin with no formal scientific training, deliberately subjected himself to hundreds of snakebites and venom injections in an effort to build immunity that could contribute to the development of a broad-spectrum antivenom.

His self-directed experiment, conducted largely in the basement of his home, has now drawn scientific attention as researchers attempt to translate his immune response into a scalable medical solution.

Friede reported that his actions were motivated by the global burden of snakebite envenoming, which accounts for an estimated 138,000 deaths and around 400,000 cases of permanent disability or disfigurement annually. Available data indicate that as many as 5.5 million people are bitten by snakes each year, with the majority of cases occurring in low-income regions of Asia and Africa where access to timely treatment remains limited.

According to Friede, the process began in 2001 with controlled self-injections of diluted venom mixtures. Over time, he escalated exposure by allowing venomous snakes to bite him directly, typically on the forearm or fingers. The repeated exposure nearly proved fatal on multiple occasions, resulting in severe physical harm including the risk of limb loss and at least one episode that led to a coma.

Friede stated that he was aware of the risks involved but continued due to the lack of effective and widely accessible treatments for snakebite victims. “People said I was crazy,” he said, adding that some individuals attempted to dissuade him. He maintained that his actions were driven by frustration over preventable deaths in vulnerable populations.

His efforts have since intersected with formal research through his association with Centivax, a California-based biotechnology company working to develop a near-universal antivenom. The company is focusing on antibodies derived from Friede’s immune system, which were developed through repeated exposure to a wide range of snake venoms.

Jacob Glanville, chief executive of Centivax, said Friede had been exposed to venom from highly lethal snake species, describing the toxins as potent enough to kill large animals under normal circumstances. A study conducted last year found that replicated antibodies based on Friede’s immune response were capable of neutralizing toxins from 19 species within the elapid family.

This group includes a significant proportion of medically important venomous snakes such as cobras, mambas, taipans, coral snakes and kraits.The findings suggest potential for broader application compared to conventional antivenoms, which are typically species-specific and require precise identification of the snake responsible for a bite.

This limitation has long complicated treatment, particularly in regions with diverse snake populations and limited diagnostic resources.Centivax plans to begin trials of the experimental antivenom on animals in Australia, with initial testing focused on pets. Human trials would follow pending further validation of safety and efficacy.

Friede said he hoped the research would demonstrate that his prolonged exposure to venom had not been in vain.The urgency of developing more effective antivenoms is underscored by environmental and demographic trends. Studies indicate that climate change may increase interactions between humans and snakes as rising temperatures alter the habitats and behavioral patterns of both.

Warmer conditions can expand the active range of snakes and shift human activity patterns, raising the likelihood of encounters.Recent incidents reflect this trend. In California’s Ventura County, six people have reportedly been bitten by rattlesnakes during an unusually warm spring season.

While isolated, such cases are consistent with broader projections that environmental change may elevate snakebite risk in certain regions.Despite the scale of the problem, global antivenom supply remains uneven. A 2021 review of antivenom resources identified insufficient manufacturing capacity to meet clinical demand, particularly in regions where production infrastructure is limited.

The report highlighted gaps in distribution systems and funding constraints, noting that antivenoms are often unavailable or unaffordable in the areas where they are most needed.Friede’s case represents an unconventional approach to a longstanding public health challenge.

Researchers emphasize that snakes themselves are not inherently aggressive toward humans and typically bite only in self-defense. From an ecological perspective, snakes play a critical role in maintaining balance within ecosystems, including controlling pest populations.Scientific understanding of venom has evolved significantly, with researchers viewing it as a complex product of evolutionary adaptation.

Venom systems have developed over more than 100 million years, predating modern mammals and reflecting highly specialized biological functions.Friede described a personal fascination with snakes that persisted despite early encounters. He said that even as a child, after being bitten by a non-lethal species, he did not develop a fear of them.

Over time, this interest evolved into sustained interaction and eventually into his self-imposed immunization effort.He characterized snakes as biologically remarkable, noting their ability to survive without limbs and to produce highly potent venom. His prolonged exposure to these animals, he said, fostered both respect and curiosity, even as it carried significant personal risk.

The broader implications of his experience are now being evaluated within a formal scientific framework, with researchers attempting to determine whether his antibodies can be adapted into a standardized treatment capable of addressing a wide spectrum of snakebite cases.